FY2023 Q3 Financial Results Presentation

from the beginning

FY2023 Q3 Financial Results Presentation

Forward-Looking Statements

1.FY2023 Q3 Financial Results

Overview of FY2023 Q3 Results

Revenue

Core Operating Profit

Profit Attributable to Owners of the Company

Revenue: Business Units (incl. Forex Impact)

Revenue: Major Products in Japan

2.FY2023 Forecast/ Annual Dividend

Revision to the forecast

Revision of Annual Dividend

3.Business Update

Revenue

Performance in Each Region (US, EU)

Performance in Each Region (Japan, ASCA)

Major Updates on Patent Disputes

Major Updates on Patent Disputes

Other Regional Initiatives

Meeting Information

4.R&D Update

5DXd ADCs Update

ENHERTU DESTINY-PanTumor02 study

Dato-DXd TROPION-Breast04 study

Dato-DXd TROPION-Breast05 study

HERTHENA-Lung01 study

HERTHENA-PanTumor01 study

I-DXd* IDeate-Lung02 study**

REJOICE-Ovarian01 study

Other clinical progresses and regulatory updates

Next Wave Update

VALENTINE-PTCL01 Primary Results

Approval of COVID-19 vaccine

Ph1b/2 study start

News Flow

FY2023, FY2024News Flow

5.Appendix

Major R&D Milestones (ENHERTU)

Major R&D Milestones (DatoDXd)

Major R&D Milestones

Major R&D Milestones (Next Wave)

Major R&D Pipeline: 5DXd ADCs

Major R&D Pipeline: Next Wave

@

Q&A

• Q&A 1

• Q&A 2

• Q&A 3

• Q&A 4

• Q&A 5